43,093 results match your criteria natriuretic peptide


Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension.

Am J Respir Crit Care Med 2022 Jan 26. Epub 2022 Jan 26.

Imperial College London, London, United Kingdom of Great Britain and Northern Ireland;

Rationale: N-terminal pro-brain natriuretic peptide (NT-proBNP), a biomarker of cardiac origin, is used to risk stratify patients with pulmonary arterial hypertension (PAH). Its limitations include poor sensitivity to early vascular pathology. Other biomarkers of vascular or systemic origin may also be useful in the management of PAH. Read More

View Article and Full-Text PDF
January 2022

Natriuretic Peptide-Based Inclusion Criteria in Heart Failure with Preserved Ejection Fraction Clinical Trials: Insights from PARAGON-HF.

Eur J Heart Fail 2022 Jan 26. Epub 2022 Jan 26.

Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Aim: Natriuretic peptides (NPs) are now routinely incorporated as key inclusion criteria in clinical trials of heart failure with preserved ejection fraction (HFpEF) as objective measures of risk. An early amendment in PARAGON-HF required all participants to have elevated NP concentrations, but some were enrolled pre-amendment, providing a unique opportunity to understand the influence of enrollment pathway in HFpEF clinical trials.

Methods And Results: Among 4,796 participants in PARAGON-HF, 193 (4. Read More

View Article and Full-Text PDF
January 2022

Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy.

BMC Med 2022 Jan 26;20(1):21. Epub 2022 Jan 26.

State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167, Beilishi Road, Xicheng District, 100037, Beijing, People's Republic of China.

Background: Heart failure with preserved ejection fraction (HFpEF) is the dominant form of heart failure (HF). We here aimed to investigate the characteristics and prognosis of HFpEF in patients with hypertrophic cardiomyopathy (HCM).

Methods: This was a prospective cohort study and patients with HCM with available NT-proBNP results were enrolled. Read More

View Article and Full-Text PDF
January 2022

Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial.

PLoS One 2022 25;17(1):e0261445. Epub 2022 Jan 25.

Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Japan.

Background: The benefits of xanthine oxidase inhibitors to chronic heart failure (CHF) patients is controversial. We investigated the beneficial effects of a novel xanthine oxidoreductase inhibitor, topiroxostat, in patients with CHF and hyperuricemia (HU), in comparison to allopurinol.

Methods And Results: The prospective, randomized open-label, blinded-end-point study was performed in 141 patients with CHF and HU at 4 centers. Read More

View Article and Full-Text PDF
January 2022

Nutritional status and its association with in-hospital major adverse cardiac events in patients with severe heart failure: a prospective study.

Nutr Hosp 2022 Jan 25. Epub 2022 Jan 25.

Department of Emergency Medicine. Qilu Hospital. Shandong University.

Objectives: this study aimed to evaluate the relationship of Nutritional Risk Screening 2002 (NRS2002) and in-hospital major adverse cardiac events (MACE) in patients with severe heart failure.

Methods: an observational study was conducted at the emergency intensive care units (EICU) of Shandong University Qilu Hospital from January 2017 to December 2019. Nutritional screening and assessment were performed at the time of admission to hospital with the NRS2002. Read More

View Article and Full-Text PDF
January 2022

Risk Stratification of Pulmonary Thromboembolism using Brain Natriuretic Peptide and Troponin I; a Brief Report.

Arch Acad Emerg Med 2022 8;10(1):e8. Epub 2022 Jan 8.

Department of Emergency Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Introduction: Pulmonary thromboembolism (PTE) is one of the most prevalent medical disorders, with a notable annual fatality rate. This study aimed to evaluated the accuracy of serum pro-BNP and troponin I levels in PTE diagnosis.

Methods: This cross-sectional study was implemented on 267 patients with suspected PTE (sudden chest pain or sudden dyspnea) in Imam Reza Hospital in Mashhad, Iran. Read More

View Article and Full-Text PDF
January 2022

Plasma brain natriuretic peptide, platelet parameters, and cardiopulmonary function in chronic obstructive pulmonary disease.

World J Clin Cases 2021 Dec;9(36):11165-11172

Department of Cardiology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.

Background: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease with worldwide occurrence and high disability and mortality rate. It occurs mostly in the elderly population with pulmonary heart disease, type II respiratory failure, and other serious complications.

Aim: To investigate the correlation of plasma brain natriuretic peptide (BNP) and platelet parameters with cardiac function and pulmonary hypertension in patients with COPD and pulmonary heart disease. Read More

View Article and Full-Text PDF
December 2021

Serum N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker of Critical Pulmonary Stenosis in Neonates.

Front Pediatr 2021 5;9:788715. Epub 2022 Jan 5.

Department of Neonatology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

To determine the efficacy of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in predicting critical pulmonary stenosis (CPS) in neonates. All neonates with pulmonary stenosis (PS) admitted to the neonatal intensive care unit of Xinhua Hospital from October 2014 to December 2020 were retrospectively reviewed. Infants with serum NT-proBNP levels measured within 48 h after birth were enrolled and divided into CPS and non-CPS groups. Read More

View Article and Full-Text PDF
January 2022

Outcome of pregnancy in a contemporary cohort of adults with congenital heart disease-a 10-year, single-center experience.

Cardiovasc Diagn Ther 2021 Dec;11(6):1344-1355

Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Hospital Eppendorf, Hamburg, Germany.

Background: Pregnancy may be associated with adverse outcome in women with congenital heart disease (CHD). However, data regarding the outcome of pregnancy in women with CHD who receive care in cardiac-obstetric expert units are limited.

Methods: We retrospectively analyzed baseline characteristics and outcome of pregnancy in 67 females with CHD who received medical care in our tertiary center for 61 singleton and 6 twin pregnancies between 2009 and 2018. Read More

View Article and Full-Text PDF
December 2021

ELABELA acts as a protective biomarker in patients with atrial fibrillation.

J Thorac Dis 2021 Dec;13(12):6876-6884

Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Background: Atrial fibrillation (AF) is the most common type of clinical arrhythmia. An early diagnosis can be beneficial in the prevention of complications, such as heart failure (HF) and stroke. In this study, we revealed that ELABELA (ELA) acts as a protective factor in patients with arrhythmia and could serve as a prognostic marker for AF and its associated complication of HF. Read More

View Article and Full-Text PDF
December 2021

A 15-year-old with chest pain: An unexpected etiology.

SAGE Open Med Case Rep 2022 19;10:2050313X211069026. Epub 2022 Jan 19.

The University of Illinois College of Medicine at Peoria, Peoria, IL, USA.

A 15-year-old female with no significant past medical history presented to the emergency department with 1 day of substernal and pleuritic chest pain, chills, cough, and hematuria. She also had swelling of the face and ankles that resolved by presentation. She was found to have elevated troponin and brain natriuretic peptide during initial workup. Read More

View Article and Full-Text PDF
January 2022

Elevated Serum Fibroblast Growth Factor 21 Is Relevant to Heart Failure Patients with Reduced Ejection Fraction.

Comput Math Methods Med 2022 11;2022:7138776. Epub 2022 Jan 11.

Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, 87 Dingjiaqiao, Nanjing, Jiangsu 210009, China.

Objective: The aim of this study was to evaluate the roles of fibroblast growth factor 21 (FGF21) in heart failure patients with reduced ejection fraction and its association with Heart Failure with reduced Ejection Fraction (HFrEF).

Methods: The level of FGF21 was measured by enzyme-linked immunosorbent assay (ELISA) in 199 subjects enrolled in this study, including 128 subjects with HFrEF and 71 control subjects. The mean follow-up time was 13. Read More

View Article and Full-Text PDF
January 2022

Diagnosis and Management of Cirrhotic Cardiomyopathy.

J Clin Exp Hepatol 2022 Jan-Feb;12(1):186-199. Epub 2021 Aug 21.

Department of Hepatology, Postgraduate Institute of Medical Education and Research, 60012, Chandigarh, India.

Background: Cirrhotic cardiomyopathy refers to the structural and functional changes in the heart leading to either impaired systolic, diastolic, electrocardiographic, and neurohormonal changes associated with cirrhosis and portal hypertension. Cirrhotic cardiomyopathy is present in 50% of patients with cirrhosis and is clinically seen as impaired contractility, diastolic dysfunction, hyperdynamic circulation, and electromechanical desynchrony such as QT prolongation. In this review, we will discuss the cardiac physiology principles underlying cirrhotic cardiomyopathy, imaging techniques such as cardiac magnetic resonance imaging and scintigraphy, cardiac biomarkers, and newer echocardiographic techniques such as tissue Doppler imaging and speckle tracking, and emerging treatments to improve outcomes. Read More

View Article and Full-Text PDF

Application of integrated management bundle incorporating with multidisciplinary measures improved in-hospital outcomes and early survival in geriatric hip fracture patients with perioperative heart failure: a retrospective cohort study.

Aging Clin Exp Res 2022 Jan 24. Epub 2022 Jan 24.

Department of Orthopaedic Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050051, People's Republic of China.

Background: In elderly, hip fracture is often complicated by perioperative heart failure, related to worse prognosis. We aimed to analyze the effects of integrated management bundle incorporating with multidisciplinary measures on in-hospital outcomes and early survival in elderly hip fracture patients with perioperative heart failure.

Methods: In this retrospective cohort study, a total of 421 hip fracture patients aged 65 and over who developed perioperative heart failure were included. Read More

View Article and Full-Text PDF
January 2022

Can we predict risk for cardiac involvement in paediatric multisystem inflammatory syndrome?

Cardiol Young 2022 Jan 24:1-21. Epub 2022 Jan 24.

Basaksehir Cam and Sakura City Hospital, Department of Pediatrics, Division of Pediatric Cardiology.

Introduction: Increasing recognition of paediatric multisystem inflammatory syndrome (PIMS) is a cause of concern. This study aimed to evaluate children with PIMS and compare the clinical and laboratory features of children with and without cardiac involvement.

Material And Methods: We conducted a prospective single-center study including 57 (male 37, 65%) patients with PIMS at a tertiary care hospital between November 2020 and March 2021. Read More

View Article and Full-Text PDF
January 2022

Red blood cell distribution width and maximum left ventricular wall thickness predict poor outcomes in patients with hypertrophic cardiomyopathy.

Echocardiography 2022 Jan 23. Epub 2022 Jan 23.

Department of Cardiology, The Jiangmen Central Hospital, The Jiangmen Central Hospital of Sun Yat-Set University, Jiangmen, China.

Aim: To evaluate the prognostic utility of red blood cell distribution width (RDW) and maximum left ventricular wall thickness (MLVWT) in patients with hypertrophic cardiomyopathy (HCM).

Patients And Methods: This study is a retrospective cohort analysis. Patients diagnosed with HCM at the First Affiliated Hospital of Sun Yat-sen University from March 2014 to March 2019 were included. Read More

View Article and Full-Text PDF
January 2022

Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study.

Cardiovasc Drugs Ther 2022 Jan 23. Epub 2022 Jan 23.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

Purpose: Carvedilol demonstrated therapeutic benefits in patients with heart failure and reduced ejection fraction (HFrEF). However, it had a short half-life time mandating twice a day administration. We investigated whether slow-release carvedilol (carvedilol-SR) is non-inferior to standard immediate-release carvedilol (carvedilol-IR) in terms of clinical efficacy in patients with HFrEF. Read More

View Article and Full-Text PDF
January 2022

Clinical significance of the albumin-bilirubin score in patients with heart failure undergoing cardiac resynchronization therapy.

Heart Vessels 2022 Jan 23. Epub 2022 Jan 23.

Division of Cardiology, Department of Medicine, Nihon University School of Medicine, 30-1 Ohyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.

Despite emerging recognition of interactions between heart failure (HF) and liver dysfunction, the impact of cardiac hepatopathy on patients with HF undergoing cardiac resynchronization therapy (CRT) has not been fully elucidated. Albumin-bilirubin (ALBI) score is a new assessment of liver function. The relationship between liver dysfunction severity based on ALBI score and clinical outcomes of patients with HF receiving CRT is unclear. Read More

View Article and Full-Text PDF
January 2022

Nomogram predicting death and heart transplantation before appropriate ICD shock in dilated cardiomyopathy.

ESC Heart Fail 2022 Jan 22. Epub 2022 Jan 22.

Cardiac Arrhythmia Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 167 Bei Li Shi Road, Xicheng District, Beijing, 100037, China.

Aims: This study aimed to develop and validate a competing risk nomogram for predicting all-cause mortality and heart transplantation (HT) before first appropriate shock in non-ischaemic dilated cardiomyopathy (DCM) patients receiving implantable cardioverter-defibrillators (ICD).

Methods And Results: A total of 218 consecutive DCM patients implanted with ICD between 2010 and 2019 at our institution were retrospectively enrolled. Cox proportional hazards model was primarily built to identify variables associated with death and HT. Read More

View Article and Full-Text PDF
January 2022

Effect of perioperative levosimendan administration on postoperative N-terminal pro-B-type natriuretic peptide concentration in patients with increased cardiovascular risk factors undergoing non-cardiac surgery: protocol for the double-blind, randomised, placebo-controlled IMPROVE trial.

BMJ Open 2022 Jan 21;12(1):e058216. Epub 2022 Jan 21.

Department of Anesthesia, Intensive Care Medicine and Pain Medicine, Outcome Research Consortium, Cleveland, Ohio, USA.

Introduction: Elevated N-terminal pro-brain natriuretic peptide (NT-pro-BNP) after non-cardiac surgery is a strong predictor for cardiovascular complications and reflects increased myocardial strain. NT-pro-BNP concentrations significantly rise after non-cardiac surgery within the first 3 days. Levosimendan is a potent inotropic drug that increases calcium sensitivity to cardiac myocytes, which results in improved cardiac contractility that last for approximately 7 days. Read More

View Article and Full-Text PDF
January 2022

Prognostic Value of Tc-HMDP Scintigraphy in Elderly Patients With Chronic Heart Failure.

Heart Lung Circ 2022 Jan 18. Epub 2022 Jan 18.

Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Background: This study evaluated the prevalence and prognostic significance of cardiac transthyretin amyloidosis (ATTR) diagnosed using Tc- hydroxymethylene-diphosphonate (Tc-HMDP) scintigraphy in an elderly heart failure population.

Methods: This retrospective study included 335 patients aged >70 years with heart failure and who underwent Tc-HMDP scintigraphy due to non-cardiac reasons in three imaging centres in Finland (Kymenlaakso Central Hospital, Jorvi Central Hospital, and Meilahti University Hospital). A Perugini grade >2 and heart-to-contralateral ratio (H/CL) of ≥1. Read More

View Article and Full-Text PDF
January 2022

Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study).

Am J Cardiol 2022 Jan 18. Epub 2022 Jan 18.

Division of Cardiology, Civil Hospital, Cremona, Italy.

Data concerning the combined prognostic role of natriuretic peptide (NP) and troponin in patients with COVID-19 are lacking. The aim of the study is to evaluate the combined prognostic value of NPs and troponin in hospitalized COVID-19 patients. From March 1, 2020 to April 9, 2020, consecutive patients with COVID-19 and available data on cardiac biomarkers at admission were recruited. Read More

View Article and Full-Text PDF
January 2022

Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease - A STABILITY Substudy.

J Am Heart Assoc 2022 Jan 21:e023667. Epub 2022 Jan 21.

Department of Medical Sciences, Cardiology Uppsala University Uppsala Sweden.

BACKGROUND The obesity paradox states that patients with higher body mass index (BMI) and cardiovascular disease may experience better prognosis. However, this is less clear in patients with coronary heart disease. METHODS AND RESULTS The prospective STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial included 15 828 patients with stable coronary heart disease with 3 to 5 years' follow-up on optimal secondary preventive treatment. Read More

View Article and Full-Text PDF
January 2022

Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis.

ESC Heart Fail 2022 Jan 21. Epub 2022 Jan 21.

Department of Cardiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.

Aims: Cardiac involvement in systemic amyloidosis is a marker of particularly poor prognosis. Cardiac amyloidosis (CA) is characterized by extracellular amyloid deposits inducing heart failure and symptoms of cardiac microvascular disease. While amyloid deposition is most common in the myocardium but also seen in pericardium and endocardium, atria, and vasculature, the role of (micro-)vascular dysfunction in CA pathophysiology remains still elusive. Read More

View Article and Full-Text PDF
January 2022

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction.

Eur J Heart Fail 2022 Jan 21. Epub 2022 Jan 21.

National Heart Centre Singapore, Singapore.

Background: Little information is available on sex differences in coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF). We investigated sex-specific proteomic profiles associated with CMD in patients with HFpEF.

Methods: Using the prospective multinational PROMIS-HFpEF study (Prevalence of Microvascular Dysfunction in HFpEF; n = 182; 54. Read More

View Article and Full-Text PDF
January 2022

Relevant Biomarkers in Medical Practices: An Analysis of the Needs Addressed by an International Survey.

J Pers Med 2022 Jan 14;12(1). Epub 2022 Jan 14.

Digital Medical Hub, APHP, 75000 Paris, France.

(1) Backround: Technological advances should foster gains in physicians' efficiency. For example, a reduction of the medical decision time can be enabled by faster biological tests. The main objective of this study was to collect responses from an international panel of physicians on their needs for biomarkers and also to convey the improvement in the outcome to be made possible by the potential development of fast diagnostic tests for these biomarkers. Read More

View Article and Full-Text PDF
January 2022

Titin-Related Dilated Cardiomyopathy: The Clinical Trajectory and the Role of Circulating Biomarkers in the Clinical Assessment.

Diagnostics (Basel) 2021 Dec 22;12(1). Epub 2021 Dec 22.

Unit for Screening Studies in Inherited Cardiovascular Diseases, National Institute of Cardiology, 04-628 Warsaw, Poland.

Titin truncating variants (tv) are known as the leading cause of inherited dilated cardiomyopathy (DCM). Nevertheless, it is unclear whether circulating cardiac biomarkers are helpful in detection and risk assessment. We sought to assess 1) early indicators of cardiotitinopathy including the serum biomarkers high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in clinically stable patients, and 2) predictors of outcome among tv carriers. Read More

View Article and Full-Text PDF
December 2021

Impact of Right Heart Failure on Clinical Outcome of Left Ventricular Assist Devices (LVAD) Implantation: Single Center Experience.

Healthcare (Basel) 2022 Jan 6;10(1). Epub 2022 Jan 6.

Department for Heart Transplant, LVAD and ECMO, Clinic for Cardiac Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.

The aim of this study was to examine the incidence and significance of right heart failure (RHF) in the early and late phase of left ventricular assist device (LVAD) implantation with the identification of predictive factors for the development of RHF. This was a prospective observational analytical cohort study. The study included 92 patients who underwent LVAD implantation and for whom all necessary clinical data from the follow-up period were available, as well as unambiguous conclusions by the heart team regarding pathologies, adverse events, and complications. Read More

View Article and Full-Text PDF
January 2022

Epidemiology of Acute Heart Failure in Critically Ill Patients with COVID-19: An Analysis from the Critical Care Cardiology Trials Network.

J Card Fail 2022 Jan 17. Epub 2022 Jan 17.

Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Background: Acute heart failure (HF) is an important complication of coronavirus disease 2019 (COVID-19) and has been hypothesized to relate to inflammatory activation.

Methods: We evaluated consecutive intensive care unit (ICU) admissions for COVID-19 across 6 centers in the Critical Care Cardiology Trials Network, identifying patients with vs. without acute HF. Read More

View Article and Full-Text PDF
January 2022

Discriminative Utility of Apelin-to-NT-Pro-Brain Natriuretic Peptide Ratio for Heart Failure with Preserved Ejection Fraction among Type 2 Diabetes Mellitus Patients.

J Cardiovasc Dev Dis 2022 Jan 12;9(1). Epub 2022 Jan 12.

Internal Medicine Department, State Medical University, 69096 Zaporozhye, Ukraine.

Background: Apelin is a regulatory vasoactive peptide, which plays a pivotal role in adverse cardiac remodeling and heart failure (HF) with reduced ejection fraction. The purpose of the study was to investigate whether serum levels of apelin is associated with HF with preserved election fraction (HFpEF) in patients with T2DM.

Methods: The study retrospectively involved 101 T2DM patients aged 41 to 62 years (48 patients with HFpEF and 28 non-HFpEF patients). Read More

View Article and Full-Text PDF
January 2022